T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.36% |
| 2 | Healthcare | 16.09% |
| 3 | Consumer Discretionary | 15.79% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CPLG
2501
DELISTED
CorePoint Lodging Inc. Common Stock
CPLG
| $378K | ﹤0.01% |
24,085
-700
| -3% | -$11K |
|
2502
Invesco Mortgage Capital
IVR
$805M
| $377K | ﹤0.01% |
13,557
-276
| -2% | -$8.55K |
|
2503
National Healthcare
NHC
$3.44B
| $377K | ﹤0.01% |
5,556
+1,178
| +27% | +$81.5K |
|
2504
CarParts.com
PRTS
$50.3M
| $375K | ﹤0.01% |
3,350
+1,690
| +102% | +$233K |
|
2505
MacroGenics
MGNX
$259M
| $373K | ﹤0.01% |
23,267
-14,200
| -38% | -$267K |
|
2506
TFS Financial
TFSL
$4.93B
| $373K | ﹤0.01% |
20,869
-278
| -1% | -$5.3K |
|
|
ALX
2507
Alexander's
ALX
$1.4B
| $372K | ﹤0.01% |
1,428
-34
| -2% | -$9.12K |
|
|
BCLI
2508
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
| $372K | ﹤0.01% |
6,200
| – | – |
|
2509
New Fortress Energy
NFE
$93M
| $372K | ﹤0.01% |
15,400
+417
| +3% | +$11.6K |
|
|
GRTS
2510
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $372K | ﹤0.01% |
28,956
-2,188
| -7% | -$24.2K |
|
2511
Spruce Power Holding Corp
SPRU
$33.6M
| $368K | ﹤0.01% |
+13,905
| New | +$537K |
|
|
NWLI
2512
DELISTED
National Western Life Group, Inc. Class A
NWLI
| $368K | ﹤0.01% |
1,715
-52
| -3% | -$11.3K |
|
|
BTRS
2513
DELISTED
BTRS Holdings Inc. Class 1 Common Stock
BTRS
| $368K | ﹤0.01% |
+47,077
| New | +$408K |
|
2514
IDT Corp
IDT
$1.67B
| $367K | ﹤0.01% |
8,309
+1,279
| +18% | +$65K |
|
2515
Aptevo Therapeutics
APVO
$5.16M
| – | – |
0
| – | – |
|
2516
Immersion
IMMR
$248M
| $364K | ﹤0.01% |
63,800
+24,800
| +64% | +$163K |
|
2517
Telos
TLS
$344M
| $363K | ﹤0.01% |
+23,524
| New | +$501K |
|
2518
AnaptysBio
ANAB
$1.66B
| $361K | ﹤0.01% |
10,397
+2,257
| +28% | +$71.6K |
|
2519
Cars.com
CARS
$672M
| $358K | ﹤0.01% |
22,255
-1,112
| -5% | -$15.9K |
|
|
UHT
2520
Universal Health Realty Income Trust
UHT
$573M
| $357K | ﹤0.01% |
5,999
+2,292
| +62% | +$133K |
|
2521
Atara Biotherapeutics
ATRA
$76.7M
| $355K | ﹤0.01% |
900
-469
| -34% | -$197K |
|
2522
Root
ROOT
$772M
| $355K | ﹤0.01% |
+6,367
| New | +$498K |
|
|
CAMP
2523
DELISTED
CalAmp Corp.
CAMP
| $355K | ﹤0.01% |
2,187
-26
| -1% | -$5.76K |
|
2524
Oportun Financial
OPRT
$351M
| $354K | ﹤0.01% |
17,472
+2,868
| +20% | +$67K |
|
2525
Porch Group
PRCH
$1.92B
| $354K | ﹤0.01% |
+22,716
| New | +$437K |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.